Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this pandemic rest on the development of effective interventions. Two monoclonal antibody (mAb) therapeutics have received emergency use authorization(1,2), and more are in the pi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Pengfei, Liu, Lihong, Iketani, Sho, Luo, Yang, Guo, Yicheng, Wang, Maple, Yu, Jian, Zhang, Baoshan, Kwong, Peter D., Graham, Barney S., Mascola, John R., Chang, Jennifer Y., Yin, Michael T., Sobieszczyk, Magdalena, Kyratsous, Christos A., Shapiro, Lawrence, Sheng, Zizhang, Nair, Manoj S., Huang, Yaoxing, Ho, David D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852232/
https://www.ncbi.nlm.nih.gov/pubmed/33532763
http://dx.doi.org/10.21203/rs.3.rs-155394/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852232/
https://www.ncbi.nlm.nih.gov/pubmed/33532763
http://dx.doi.org/10.21203/rs.3.rs-155394/v1

Ejemplares similares